Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations

The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.

[1]  J. Emerson,et al.  Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. , 2007, Chest.

[2]  T. Marco,et al.  Home intravenous antibiotics for cystic fibrosis. , 2000, The Cochrane database of systematic reviews.

[3]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[4]  J. Lapointe,et al.  Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa , 1995, Antimicrobial agents and chemotherapy.

[5]  S. Lewis,et al.  Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC study: a randomised controlled trial , 2005, The Lancet.

[6]  J. Bosso,et al.  Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. , 1987, The American journal of medicine.

[7]  P. Bye,et al.  Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial , 2005, The Lancet.

[8]  R. Swartz,et al.  Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. , 1998, The New England journal of medicine.

[9]  J. Turnidge,et al.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. , 1988, The Journal of infectious diseases.

[10]  J. Ledbetter,et al.  Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. , 1985, The Journal of pediatrics.

[11]  U. Schaad,et al.  Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group. , 1997, The Pediatric infectious disease journal.

[12]  A. Giunta,et al.  Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. , 1987, The Pediatric infectious disease journal.

[13]  W. Craig Re-evaluating current antibiotic therapy , 2001 .

[14]  J. Littlewood,et al.  Home intravenous antibiotic treatment in cystic fibrosis. , 1988, Archives of disease in childhood.

[15]  M. Marks,et al.  Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? , 1980, The Journal of pediatrics.

[16]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[17]  A. Prince,et al.  Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Gonzalez de Dios,et al.  Home intravenous antibiotics for cystic fibrosis. , 2000, The Cochrane database of systematic reviews.

[19]  L. Saiman,et al.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.

[20]  M. Hodson,et al.  Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. , 2000, The European respiratory journal.

[21]  R. Moore,et al.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. , 1984, The Journal of infectious diseases.

[22]  W. Craig The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy. , 2001, Respiratory medicine.

[23]  M. Tully,et al.  Clinical and economic choices in the treatment of respiratory infections in cystic fibrosis: comparing hospital and home care. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[24]  M. Sulis,et al.  Pneumothorax in pleuropulmonary Kaposi's sarcoma related to acquired immunodeficiency syndrome. , 1989, The American journal of medicine.

[25]  S. Butler,et al.  Patterns of medical practice in cystic fibrosis: Part II. Use of therapies , 1999, Pediatric pulmonology.

[26]  Charles A. Johnson,et al.  Pulmonary exacerbations in cystic fibrosis , 2004, Pediatric pulmonology.

[27]  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee. , 1985 .

[28]  T. Remmington,et al.  Oral anti-pseudomonal antibiotics for cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[29]  Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms , 1985, Thorax.

[30]  A. Quittner,et al.  Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. , 1999, Diabetes research and clinical practice.

[31]  H. Neu,et al.  Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. , 1977, The Journal of pediatrics.

[32]  D. Goldmann,et al.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. , 1983, The Journal of infectious diseases.

[33]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[34]  D. Turck,et al.  Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis , 1998, Archives of disease in childhood.

[35]  Martin H. Schmidt,et al.  Epidemiology and Pathogenesis , 2022 .

[36]  P. Baghurst,et al.  Efficacy of once‐daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: A preliminary study * , 2001, Pediatric pulmonology.

[37]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  H. Fuchs,et al.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. , 1994, The New England journal of medicine.

[39]  J. W. Wong,et al.  Mucociliary clearance in cystic fibrosis. , 1976, Modern problems in paediatrics.

[40]  S. Conway,et al.  Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. , 1997, Thorax.

[41]  G. Redding,et al.  Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis , 1999 .

[42]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[43]  R. J. Butland,et al.  ORAL CIPROFLOXACIN COMPARED WITH CONVENTIONAL INTRAVENOUS TREATMENT FOR PSEUDOMONAS AERUGINOSA INFECTION IN ADULTS WITH CYSTIC FIBROSIS , 1987, The Lancet.

[44]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[45]  K. Robinson,et al.  Cystic fibrosis pulmonary guidelines: airway clearance therapies. , 2009, Respiratory care.

[46]  B. Ramsey,et al.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. , 2003, Chest.

[47]  M. Newport,et al.  Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. , 1994, The European respiratory journal.

[48]  J. Watkins,et al.  Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa? , 1988, Scandinavian Journal of Gastroenterology, Supplement.

[49]  M. Walshaw,et al.  Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use , 2005, Pediatric pulmonology.

[50]  M. Jackson,et al.  Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. , 1986, Pediatric infectious disease.

[51]  M. Hodson,et al.  Inhalation of antibiotics in cystic fibrosis. , 1995, The European respiratory journal.

[52]  S. Bowler,et al.  Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. , 1997, The European respiratory journal.

[53]  I. Abdulhamid,et al.  Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis , 2006, Pediatric pulmonology.

[54]  G. Esmond,et al.  Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis. , 2006, Journal of clinical nursing.

[55]  Hodson,et al.  Adults with cystic fibrosis , 1990, The Lancet.

[56]  W. Ambrosius,et al.  Lower respiratory illness in infants and young children with cystic fibrosis , 1997, Pediatric pulmonology.

[57]  P. Gilligan,et al.  Microbiology of airway disease in patients with cystic fibrosis , 1991, Clinical Microbiology Reviews.

[58]  A. Knox,et al.  Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers , 2002, Pediatric pulmonology.

[59]  J. Bosso,et al.  Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. , 1988, The Pediatric infectious disease journal.

[60]  N. Høiby,et al.  Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. , 1986, Scandinavian journal of infectious diseases.

[61]  S. Davis,et al.  Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Bacterial Infectious Diseases , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[62]  R. Hornung,et al.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. , 2002, Chest.

[63]  D. Geddes,et al.  SELF-ADMINISTERED HOME INTRAVENOUS ANTIBIOTIC THERAPY IN BRONCHIECTASIS AND ADULT CYSTIC FIBROSIS , 1984, The Lancet.

[64]  Bowerman,et al.  Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis , 2000, European journal of clinical investigation.

[65]  D. Nielson,et al.  Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis , 1997, Pediatric pulmonology.

[66]  M. Falagas,et al.  Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. , 2008, The Journal of antimicrobial chemotherapy.

[67]  J. Blumer,et al.  Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis , 1988, Pediatric pulmonology.

[68]  R. Moore,et al.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. , 1984, The American journal of medicine.

[69]  E. Atenafu,et al.  Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. , 2007, The Journal of antimicrobial chemotherapy.

[70]  D. Bilton,et al.  Evaluation of Once Daily Tobramycin Versus the Traditional Three Time Daily for the Treatment of Acute Pulmonary Exacerbations in Adult Cystic Fibrosis Patients , 2006 .

[71]  G. Redding,et al.  Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. , 1999, The Journal of pediatrics.

[72]  L. Briceland,et al.  Single Daily Dosing of Aminoglycosides , 1995, Pharmacotherapy.

[73]  J. Bosso,et al.  A Pilot Study of the Efficacy of Constant‐Infusion Ceftazidime in the Treatment of Endobronchial Infections in Adults with Cystic Fibrosis , 1999, Pharmacotherapy.

[74]  Diana Petitti,et al.  Update on the Methods of the U.S. Preventive Services Task Force: Estimating Certainty and Magnitude of Net Benefit , 2007, Annals of Internal Medicine.

[75]  J. Bosso Use of ciprofloxacin in cystic fibrosis patients. , 1989, The American journal of medicine.

[76]  L. Saiman Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. , 2007, Paediatric respiratory reviews.

[77]  W. Warwick,et al.  Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. , 1990, The American review of respiratory disease.

[78]  M. Yi,et al.  The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? , 2004, The Journal of pediatrics.

[79]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[80]  S. Bogle,et al.  Once-daily tobramycin in the treatment of adult patients with cystic fibrosis , 2002, European Respiratory Journal.

[81]  H. Levison,et al.  Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. , 1985, Pediatric infectious disease.

[82]  J. Bradley,et al.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis , 1999, Irish journal of medical science.

[83]  J. Ioannidis,et al.  Single or multiple daily doses of aminoglycosides: a meta- analysis , 1996, BMJ.

[84]  E. Mellits,et al.  A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. , 1981, The Journal of pediatrics.

[85]  H. Auerbach,et al.  Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. , 1987, The Journal of pediatrics.

[86]  A. Smyth,et al.  Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2017, The Cochrane database of systematic reviews.

[87]  M S Pepe,et al.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.

[88]  S. Aaron Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms. , 2007, Paediatric respiratory reviews.

[89]  R. Baker,et al.  Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis , 2002, Journal of pediatric gastroenterology and nutrition.

[90]  M. Konstan,et al.  Shifting patterns of inhaled antibiotic use in cystic fibrosis , 2008, Pediatric pulmonology.

[91]  D. Nicolau Pharmacodynamic optimization of β-lactams in the patient care setting , 2008, Critical care.